CompletedPhase 3NCT02853474
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Oscar Lambret
- Principal Investigator
- Arlette Da Silva, MDCentre Oscar Lambret
- Intervention
- Early Palliative Care visit(behavioral)
- Enrollment
- 480 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2022
Study locations (20)
- Institut de cancérologie de l'Ouest-site PAUL, Angers, France
- CH de Béthune, Beuvry, France
- Centre Hospitalier Boulogne sur Mer, Boulogne-sur-Mer, France
- Centre François Baclesse, Caen, Caen, France
- Centre Georges Francois Leclerc de DIJON, Dijon, France
- Centre Oscar Lambret, Lille, France
- Hôpital Saint Vincent de Paul, Lille, France
- CHRU, Hôpital Claude HURIEZ, Lille, France
- Centre Léon Bérard de LYON, Lyon, France
- Institut Paoli-Calmettes de MARSEILLE, Marseille, France
- Institut du Cancer de Montpellier, Montpellier, France
- Institut de cancérologie de Lorraine, Nancy, Nancy, France
- Institut de cancérologie de l'Ouest, Nantes, Nantes, France
- Centre Antoine LACASSAGNE DE NICE, Nice, France
- Institut Curie, site de Saint Cloud, Hopital, Saint-Cloud, France
- +5 more locations on ClinicalTrials.gov
Collaborators
Ligue contre le cancer, France · Région Nord-Pas de Calais, France · National Cancer Institute, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02853474 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNCT07206355In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary CancersUniversity of Nottingham